Impact of the pre-biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study.

David Thein Mia-Louise Nielsen Julia-Tatjana Maul Simon Francis Thomsen Jacob Pontoppidan Thyssen Alexander Egeberg

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

None of the three exposures used to assess the complexity of the pre-biologic treatment journey appeared to impact drug survival. As long as patients experience adequate disease control, these results suggest that conventional systemic treatment do not negatively impact the drug survival of subsequent biologics.

Keyphrases

rheumatoid arthritis
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
free survival
adverse drug
hidradenitis suppurativa